HRP20161631T1 - Dihidropirazolni gpr40 modulatori - Google Patents

Dihidropirazolni gpr40 modulatori Download PDF

Info

Publication number
HRP20161631T1
HRP20161631T1 HRP20161631TT HRP20161631T HRP20161631T1 HR P20161631 T1 HRP20161631 T1 HR P20161631T1 HR P20161631T T HRP20161631T T HR P20161631TT HR P20161631 T HRP20161631 T HR P20161631T HR P20161631 T1 HRP20161631 T1 HR P20161631T1
Authority
HR
Croatia
Prior art keywords
image
agents
compound
alkyl
independently
Prior art date
Application number
HRP20161631TT
Other languages
English (en)
Croatian (hr)
Inventor
Bruce A. Ellsworth
Jun Shi
William R. Ewing
Elizabeth A. Jurica
Andres S. Hernandez
Ximao Wu
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20161631T1 publication Critical patent/HRP20161631T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Optical Integrated Circuits (AREA)
HRP20161631TT 2012-11-16 2013-11-15 Dihidropirazolni gpr40 modulatori HRP20161631T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261727262P 2012-11-16 2012-11-16
US201361777294P 2013-03-12 2013-03-12
PCT/US2013/070215 WO2014078610A1 (en) 2012-11-16 2013-11-15 Dihydropyrazole gpr40 modulators
EP13811645.4A EP2920165B1 (en) 2012-11-16 2013-11-15 Dihydropyrazole gpr40 modulators

Publications (1)

Publication Number Publication Date
HRP20161631T1 true HRP20161631T1 (hr) 2017-01-13

Family

ID=49876965

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161631TT HRP20161631T1 (hr) 2012-11-16 2013-11-15 Dihidropirazolni gpr40 modulatori

Country Status (26)

Country Link
US (1) US9133163B2 (enExample)
EP (1) EP2920165B1 (enExample)
JP (1) JP6322203B2 (enExample)
KR (1) KR102204804B1 (enExample)
CN (1) CN104812748B (enExample)
AU (1) AU2013344604B2 (enExample)
BR (1) BR112015010779A2 (enExample)
CA (1) CA2891574A1 (enExample)
CY (1) CY1118365T1 (enExample)
DK (1) DK2920165T3 (enExample)
EA (1) EA026913B1 (enExample)
ES (1) ES2606685T3 (enExample)
HR (1) HRP20161631T1 (enExample)
HU (1) HUE032401T2 (enExample)
IL (1) IL238741A0 (enExample)
LT (1) LT2920165T (enExample)
MX (1) MX358499B (enExample)
PL (1) PL2920165T3 (enExample)
PT (1) PT2920165T (enExample)
RS (1) RS55363B1 (enExample)
SG (1) SG11201503558SA (enExample)
SI (1) SI2920165T1 (enExample)
SM (1) SMT201600410B (enExample)
TW (1) TW201427971A (enExample)
UY (1) UY35143A (enExample)
WO (1) WO2014078610A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005858A (es) * 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
KR20160077213A (ko) 2013-11-14 2016-07-01 카딜라 핼쓰캐어 리미티드 새로운 헤테로시클릭 화합물
KR102336370B1 (ko) * 2014-05-07 2021-12-06 브리스톨-마이어스 스큅 컴퍼니 당뇨병과 같은 질환의 치료를 위한 피롤리딘 gpr40 조정제
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177285B1 (en) 2014-08-08 2020-09-23 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
CA3058578A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102625712B1 (ko) 2018-07-13 2024-01-19 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN115490638A (zh) * 2022-09-22 2022-12-20 哈尔滨理工大学 5-官能团化吡唑啉及其制备方法
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用
CN119431272B (zh) * 2024-11-13 2025-07-25 北京斯利安药业有限公司 （s）-3-甲基-（2-哌啶基苯基）-1-丁胺乙酰谷氨酸盐的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP2007522252A (ja) * 2004-02-17 2007-08-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 置換ピラゾリン化合物、その調製および医薬品としてのその使用
EP1637522A1 (en) * 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1743894A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
US8153694B2 (en) 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
EP2001844A2 (en) 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
KR101058772B1 (ko) 2006-06-27 2011-08-24 다케다 야쿠힌 고교 가부시키가이샤 융합 환형 화합물
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
CA2667249A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008130514A1 (en) 2007-04-16 2008-10-30 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
AR070898A1 (es) * 2008-03-18 2010-05-12 Solvay Pharm Bv Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
US8236821B2 (en) * 2008-05-19 2012-08-07 Jenrin Discovery, Inc. Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
MX2012003389A (es) * 2009-10-06 2012-04-10 Bristol Myers Squibb Co Moduladores de gpr40 de pirrolidina.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
JP5946192B2 (ja) 2010-11-18 2016-07-05 ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬
AU2011333472A1 (en) * 2010-11-26 2013-06-06 Lupin Limited Bicyclic GPR119 modulators
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
US9326218B2 (en) * 2012-11-02 2016-04-26 Telefonaktiebolaget L M Ericsson (Publ) Base-station-to-base-station gateway and related devices, methods, and systems
MX2015005858A (es) * 2012-11-16 2015-09-24 Bristol Myers Squibb Co Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
US8962660B2 (en) * 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators

Also Published As

Publication number Publication date
ES2606685T3 (es) 2017-03-27
HUE032401T2 (en) 2017-09-28
CN104812748A (zh) 2015-07-29
SI2920165T1 (sl) 2017-02-28
WO2014078610A1 (en) 2014-05-22
EA026913B1 (ru) 2017-05-31
CN104812748B (zh) 2017-10-24
KR20150082616A (ko) 2015-07-15
BR112015010779A2 (pt) 2017-07-11
AU2013344604B2 (en) 2017-07-27
US9133163B2 (en) 2015-09-15
EA201590954A1 (ru) 2015-08-31
JP2016500063A (ja) 2016-01-07
MX2015005735A (es) 2015-09-16
CY1118365T1 (el) 2017-06-28
DK2920165T3 (en) 2017-01-16
AU2013344604A1 (en) 2015-07-02
MX358499B (es) 2018-08-23
KR102204804B1 (ko) 2021-01-18
PL2920165T3 (pl) 2017-04-28
UY35143A (es) 2014-05-30
PT2920165T (pt) 2016-12-20
IL238741A0 (en) 2015-06-30
JP6322203B2 (ja) 2018-05-09
EP2920165B1 (en) 2016-09-28
TW201427971A (zh) 2014-07-16
SMT201600410B (it) 2017-01-10
SG11201503558SA (en) 2015-06-29
LT2920165T (lt) 2016-12-12
RS55363B1 (sr) 2017-03-31
US20140142139A1 (en) 2014-05-22
CA2891574A1 (en) 2014-05-22
EP2920165A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
HRP20161631T1 (hr) Dihidropirazolni gpr40 modulatori
JP2014518853A5 (enExample)
JP2016500063A5 (enExample)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
CA2889446C (en) Combination therapies for the treatment of alzheimer&#39;s disease and related disorders
JP2009522292A5 (enExample)
CA2798610A1 (en) Bicyclic heteroaryl compounds as gpr119 modulators
KR102610573B1 (ko) 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
JP2024050527A5 (enExample)
JP6238460B2 (ja) 脂質異常症治療剤
JP2010501567A5 (enExample)
JP2009503107A5 (enExample)
HRP20160678T1 (hr) Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina
JP2017508794A5 (enExample)
SI3140296T1 (en) PIROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES AS SUITABLE DISEASE
JP2004504301A5 (enExample)
HRP20141048T1 (hr) Spojevi, pripravci i metode
HRP20110552T1 (hr) DERIVATI 1,2,3-TRIAZOLA, NAMIJENJENI UPOTREBI KAO INHIBITORI STEAROIL-CoA-DESATURAZE
JP2010508288A5 (enExample)
JP2004529931A5 (enExample)
JP2017508795A5 (enExample)
AR117640A1 (es) Compuestos de 2,6-diaminopiridina como inhibidores de khk
JP3125319B2 (ja) 水難溶性薬物の医薬組成物
KR890008104A (ko) 디아릴스티릴퀴놀린 이산
RU2015142383A (ru) Новейшие антагонисты trpa1-рецепторов